Non-alcoholic fatty liver disease affects 1 in 4 people globally. There are currently no medications available for this untreatable condition. Following a research study, this could change. At the Scottish University, Professor Lora Heisler and Dr Fiona Murray along with a team of international scientists leading the study. Groundbreaking research at Aberdeen University makes a breakthrough in treating liver disease. The research from this study can in turn result in medication being available to treat this condition.
This is a great step forward since the advanced stage of non-alcoholic fatty liver disease often leads to cirrhosis of the liver. And finally the only option is a liver transplant. This important breakthrough in research at Aberdeen University emphasises a prospective drug target for non-alcoholic fatty liver disease. This research at Aberdeen University makes a breakthrough in treating liver disease. Their research aims to identify novel targets that can aid in the diagnosis and management of metabolic disorders and associated conditions. Such as diabetes, high blood pressure, heart disease, and non-alcoholic fatty liver disease.
400,000 Individuals were Researched
From UK Biobank more than 400,000 individuals were researched in the study. Researchers’ findings are that certain variations in the GPR75 gene are associated with being slim and having a reduced risk of developing hepatic steatosis.
In addition, the study reveals that when GPR75 is eliminated in mice. It prevents the accumulation of fat in the liver after consuming a Western diet.
The research paper is published in Cell Metabolism
EJY Medical Writing 